CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5 enrolled
Drug / intervention
XIAFLEXbiological
Likely dose
XIAFLEX 0.58 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01450397
NCT01450397Phase 4Completed
CompareCT.gov

MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

Hospital for Special Surgery, New York·interventional·Posted Oct 12, 2011·Updated Apr 17, 2017

In Brief

A Phase 4 clinical trial evaluating XIAFLEX for Dupuytren's Disease. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of XIAFLEX on your finger through MRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDupuytren's Disease
CountriesUnited States
CollaboratorsAuxilium Pharmaceuticals, Inc.

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 12, 2011
Enrollment StartMar 1, 2011
Primary CompletionJan 1, 2012
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.7 years ago

Interventions

XIAFLEXbiological

One Injection of 0.58 mg of Xiaflex into the affected area of the hand.